Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils

Pharmacology Biochemistry and Behavior

Volumn 83, Issue 4, 2006, Pages 533-539

  Salome N ^a   Stemmelin, J ^a   Cohen, C ^a   Griebel, G ^a  

^a SANOFI   (France)

Author keywords

Anxiety; Depression; Gerbils; Neurokinin receptor; Osanetant; Saredutant; Social interaction; Tonic immobility

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 2 [1 [2 [4 [2 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ACETYL] 2 (3,4 DICHLOROPHENYL) 2 MORPHOLINYL]ETHYL] 4 PIPERIDINYL] 2 METHYLPROPANAMIDE; BUSPIRONE; DIAZEPAM; FLUOXETINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; OSANETANT; SAREDUTANT; SSR 240600; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; GERBIL; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; SOCIAL INTERACTION; TONIC IMMOBILITY; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; GERBILLINAE; IMMOBILIZATION; MALE; MOTOR ACTIVITY; PIPERIDINES; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROKININ-3; SOCIAL BEHAVIOR;

GERBILLINAE;

EID: 33744516123     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.03.013     Document Type: Article

References (58)

1. Bensaid M., Faucheux B.A., Hirsch E., Agid Y., Soubrie P., and Oury-Donat F. Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 303 (2001) 25-28
2. Beresford I.J., Birch P.J., Hagan R., and Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 104 (1991) 292-293
3. Bilkei-Gorzo A., Racz I., Michel K., and Zimmer A. Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 22 (2002) 10046-10052
4. Bondy B., Baghai T.C., Minov C., Schule C., Schwarz M.J., Zwanzger P., et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 53 (2003) 538-542
5. Brocco M., Dekeyne A., and Millan M.J. Contrasting actions of selective neurokinin1 (NK1) antagonists in rodent models of antidepressant and anxiolytic properties. Soc Neurosci Abstr 28 (2002) 68313
6. Cheeta S., Tucci S., Sabdhu J., Williams A.R., Rupniak N.M.J., and File S.E. Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 915 (2001) 170-175
7. Dableh L.J., Yashpal K., Rochford J., and Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507 (2005) 99-105
8. De Lima T.C.M., Teixeira R.M., Santos A.R.S., Rae G.A., and Calixto J.B. Behavioral effects of intracerebroventricular injection of selective tachykinin agonists and antagonists. Soc Neurosci Abstr 21 (1995) 1696
9. Emonds-Alt X., Bichon D., Ducoux J.P., Heaulme M., Miloux B., Poncelet M., et al. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci 56 (1995) PL27-PL32
10. Emonds-Alt X., Proietto V., Steinberg R., Oury-Donat F., Vigé X., Vilain P., et al. SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)-phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 303 (2002) 1171-1179
11. Emonds-Alt X., Vilain P., Goulaouic P., Proietto V., Van Broeck D., Advenier C., et al. A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci 50 (1992) PL101-PL106
12. File S.E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test in rats. Pharmacol Biochem Behav 58 (1997) 747-752
13. File S.E. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology 152 (2000) 105-109
14. File S.E., and Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 463 (2003) 35-53
15. File S.E., Cheeta S., and Akanezi C. Diazepam and nicotine increase social interaction in gerbils: a test for anxiolytic action. Brain Res 888 (2001) 311-313
16. Fundaro A. Pinch-induced catalepsy in mice: a useful model to investigate antidepressant or anxiolytic drugs. Prog Neuro-Psychopharmacol Biol Psychiat 22 (1998) 147-158
17. Gentsch C., Cutler M., Vassout A., Veenstra S., and Brugger F. Anxiolytic effect of NKP608, a NK1 receptor antagonist, in the social investigation test in gerbils. Behav Brain Res 133 (2002) 363-368
18. Griebel G. Is there a future for neuropeptides receptor ligands in the treatment of anxiety disorders?. Pharmacol Ther 82 (1999) 461-469
19. Griebel G., Perrault G., and Soubrié P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 158 (2001) 241-251
20. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. PNAS 99 (2002) 6370-6375
21. Griebel G., Simiand J., Stemmelin J., Gal C.S., and Steinberg R. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2 (2003) 191-200
22. Holmes A., Heilig M., Rupniak N.M.J., Steckler T., and Griebel G. Neuropeptide system as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24 (2003) 580-588
23. Khawaja A.M., and Rogers D.F. Tachykinins: receptor to effector. Int J Biochem Cell Biol 28 (1996) 721-738
24. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
25. Jung M., Michaud J.C., Steinberg R., Barnouin M.C., Hayar A., Mons G., et al. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience 74 (1996) 403-414
26. Loiseau F., Le Bihan C., Hamon M., and Thiebot MH. Distinct effects of diazepam and NK1 receptor antagonists in two conflict procedures in rats. Behav Pharmacol 14 (2003) 447-455
27. Maubach K.A., Rupniak N.M.J., Kramer M.S., and Hill R.G. Novel strategies for pharmacotherapy of depression. Curr Opin Chem Biol 3 (1999) 481-488
28. McLean S. Do substance P and the NK1 receptor have a role in depression and anxiety?. Curr Pharm Des 11 (2005) 1529-1547
29. Molewijk H.E., Hartog K., van der Poel A.M., Mos J., and Olivier B. Reduction of guinea-pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology 128 (1996) 31-38
30. Nikolaus S., Huston J.P., and Hasenohrl R.U. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. NeuroReport 10 (1999) 2293-2296
31. Papp M., Vassout A., and Gentsch C. The NK-1 receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 15 (2000) 19-23
32. Panocka I., Massi M., Lapo I., Swiderski T., Kowalczyk M., and Sadowski B. Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity. Peptides 22 (2001) 1037-1042
33. Pennefather J.N., Lecci A., Candenas M.L., Patak E., Pinto F.M., and Maggi C.A. Tachykinins and tachykinin receptors: a growing family. Life Sci 74 (2004) 1445-1463
34. Regoli D., Boudon A., and Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46 (1994) 551-599
35. Ribeiro S.J., and De Lima T.C. Related Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice. Neurosci Lett 258 (1998) 155-158
36. Ribeiro S.J., and De Lima T.C. Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 861-869
37. Ribeiro S.J., Teixeira R.M., Calixto J.B., and De Lima T.C.M. Tachykinin NK3 receptor involvement in anxiety. Neuropeptides 33 (1999) 181-188
38. Rigby M., O'Donnell R., and Rupniak N.M. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 490 (2005) 335-353
39. Rimon R., Le Greves P., Nyberg F., Heikkila L., Salmela L., and Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 19 (1984) 509-516
40. Rodgers R.J., Gentsch C., Hoyer D., Bryant E., Green A.J., Kolokotroni K.Z., et al. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze. Behav Brain Res 154 (2004) 183-192
41. Rupniak N.M., Carlson E.C., Harrison T., Oates B., Seward E., Owen S., et al. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39 (2000) 1413-1421
42. Rupniak N.M., Carlson E.J., Webb J.K., Harrison T., Porsolt R.D., Roux S., et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12 (2001) 497-508
43. Salomé N., Stemmelin J., Scatton B., and Griebel G. Anxiolytic-like effects of tachykinin receptor antagonists in the gerbil social interaction test. 5th World Congress on Stress vol. 18 (2004) 310
44. Santarelli L., Gobbi G., Debs P.C., Sibille E.L., Blier P., Hen R., et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. PNAS 98 (2001) 1912-1917
45. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 375 (1999) 51-60
46. Simiand J., Guitard J., Griebel G., and Soubrie P. Tonic immobility in gerbils: a new model for detecting antidepressant-like effects. Behav Pharmacol 14 Suppl1 (2003) S40
47. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Dounat F., et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotrophin-releasing factor function. J Pharmacol Exp Ther 299 (2001) 449-458
48. Steinberg R., Alonso R., Rouquier L., Desvignes C., Michaud J.C., Cudennec A., et al. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J Pharmacol Exp Ther 303 (2002) 1180-1188
49. Stratton S.C., Beresford I.J., Harvey F.J., Turpin M.P., Hagan R.M., and Tyers MB. Anxiolytic activity of the tachykinin NK2 receptor antagonists in the mouse light-dark box. Eur J Pharmacol 250 (1993) R11-R12
50. Stratton S.C., Beresford I.J.M., and Hagan RM. GR159897, a potent non-peptide tachykinin NK2 receptor antagonist, releases suppressed behaviours in a novel environment. Br J Pharmacol 112 (1994) 49
51. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., and DeLima TCM. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behaviour in mice. Eur J Pharmacol 311 (1996) 7-14
52. Varty G.B., Cohen-Williams M.E., Morgan C.A., Pylak U., Duffy R.A., Lachowicz J.E., et al. The gerbil elevated plus-maze II: anxiolytic effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27 (2002) 372-379
53. Varty G.B., Cohen-Williams M.E., and Hunter J.C. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 14 (2003) 87-95
54. Vassout A., Schaub M., Gentsch C., Ofner S., Schilling W., and Veenstra S. CGP49823, a novel NK1 receptor antagonist: behavioural effects. Neuropeptides 26 (1994) S38
55. Vassout A., Veenstra S., Hauser K., Ofner S., Brugger F., Schilling W., et al. NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul Pept 96 (2000) 7-16
56. Vendruscolo L.F., Takahashi R.N., Bruske G.R., and Ramos A. Evaluation of the anxiolytic-like effects of NKP608, a NK1 receptor antagonists, in two inbred rat strains that display genetically-determined differences in anxiety-related behaviours. Psychopharmacology 169 (2003) 287-293
57. Walsch D.M., Stratton S.C., Harvey F.J., Beresford I.J.M., and Hagan RM. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 121 (1995) 186-191
58. Zocchi A., Varnier G., Arban R., Griffante C., Zanetti L., Bettelini L., et al. Effects of antidepressant drugs and GR205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 345 (2003) 73-76